VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

S. 3311 · 118th Congress

American Made Pharmaceuticals Act of 2023

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

TSD SmithSponsor
2 cosponsors · 1 D, 1 R

1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

What it does: CRS summary · Introduced in Senate · Nov 15, 2023

American Made Pharmaceuticals Act of 2023

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: American Made Pharmaceuticals Act of 2023

Latest action (Jul 25, 2024): Committee on Banking, Housing, and Urban Affairs. Hearings held.

Policy area: Health · Origin: Senate · Introduced: Nov 15, 2023

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.